The advantage of high specificity of mAbs are fully appreciated. However, at the early days scientists have realized the limit of monospecificity and weak ADCC/CDC elicited by naked mAbs. Therefore, significant amount of effort has been invested in the antibody engineering for decades. Those efforts gained great success marked by recent approval of KADCYLA and BLINCYTO. In Alphamab, we have developed proprietary protein engineer platforms to introduce bispecificity, antibody mixture and antibody-protein hybrid. The platforms have been utilized to generated several leads.